Related Experiment Video

Updated: Sep 25, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

P2Y purinergic signaling in prostate cancer: Emerging insights into pathophysiology and therapy

Mahmoud G Khalafalla1, Hung N Tran2, Farid G Khalafalla3

  • 1Northwestern University, Feinberg School of Medicine, Department of Medicine, United States of America.

Biochimica Et Biophysica Acta. Reviews on Cancer
|April 28, 2022
PubMed

Insights

Extracellular nucleotides and P2Y purinergic receptors are crucial in prostate cancer growth. Targeting these receptors offers a promising strategy to overcome current treatment limitations.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Prostate cancer treatment faces ongoing challenges despite recent therapeutic advancements.
  • Extracellular nucleotides and their receptors are implicated in various cancer types' growth and immune evasion.
  • Understanding these mechanisms is vital for developing new prostate cancer therapies.

Purpose of the Study:

  • To review the pathological and immunomodulatory roles of P2Y purinergic nucleotide receptors in prostate cancer.
  • To explore the potential of P2Y receptors as therapeutic targets for prostate cancer.

Main Methods:

  • Literature review of studies on extracellular nucleotides and P2Y receptors in cancer.
  • Analysis of the roles of P2Y receptors in prostate cancer pathogenesis.
  • Examination of the immunomodulatory functions of P2Y receptors in the tumor microenvironment.

Main Results:

  • P2Y purinergic receptors are expressed on prostate tumor and immune cells.
  • Extracellular nucleotides modulate prostate cancer cell growth and immune responses.
  • P2Y receptors influence the tumor microenvironment and cancer progression.

Conclusions:

  • P2Y purinergic receptors are key players in prostate cancer pathology and immune modulation.
  • Targeting P2Y receptors presents a novel therapeutic avenue for prostate cancer.
  • Further research into P2Y receptor-targeted therapies could address unmet clinical needs in prostate cancer treatment.
Keywords:
Extracellular nucleotidesProstate cancerPurinergic signaling

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.2K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
264
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
660
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K